FIDIA SPA (FDA.MI) Stock Fundamental Analysis

Europe • Euronext Milan • BIT:FDA • IT0005654683

0.1214 EUR
0 (-0.33%)
Last: Jan 23, 2026, 07:00 PM
Fundamental Rating

1

Taking everything into account, FDA scores 1 out of 10 in our fundamental rating. FDA was compared to 111 industry peers in the Machinery industry. Both the profitability and financial health of FDA have multiple concerns. FDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year FDA has reported negative net income.
  • In the past year FDA had a positive cash flow from operations.
  • In the past 5 years FDA reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: FDA reported negative operating cash flow in multiple years.
FDA.MI Yearly Net Income VS EBIT VS OCF VS FCFFDA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • FDA's Return On Assets of -8.49% is on the low side compared to the rest of the industry. FDA is outperformed by 84.68% of its industry peers.
  • Looking at the Return On Equity, with a value of -53.14%, FDA is doing worse than 86.49% of the companies in the same industry.
Industry RankSector Rank
ROA -8.49%
ROE -53.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FDA.MI Yearly ROA, ROE, ROICFDA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

  • FDA has a better Gross Margin (69.64%) than 94.59% of its industry peers.
  • In the last couple of years the Gross Margin of FDA has grown nicely.
  • FDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.42%
GM growth 5Y4.76%
FDA.MI Yearly Profit, Operating, Gross MarginsFDA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

1

2. Health

2.1 Basic Checks

  • FDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for FDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FDA.MI Yearly Shares OutstandingFDA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20K 40K 60K
FDA.MI Yearly Total Debt VS Total AssetsFDA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of 0.09, we must say that FDA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of FDA (0.09) is worse than 81.08% of its industry peers.
  • The Debt to FCF ratio of FDA is 6.13, which is on the high side as it means it would take FDA, 6.13 years of fcf income to pay off all of its debts.
  • FDA has a Debt to FCF ratio of 6.13. This is comparable to the rest of the industry: FDA outperforms 47.75% of its industry peers.
  • FDA has a Debt/Equity ratio of 1.41. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.41, FDA is doing worse than 83.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF 6.13
Altman-Z 0.09
ROIC/WACCN/A
WACC8.19%
FDA.MI Yearly LT Debt VS Equity VS FCFFDA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • A Current Ratio of 1.06 indicates that FDA should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.06, FDA is not doing good in the industry: 80.18% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.46 indicates that FDA may have some problems paying its short term obligations.
  • The Quick ratio of FDA (0.46) is worse than 92.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.46
FDA.MI Yearly Current Assets VS Current LiabilitesFDA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

  • FDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.56%, which is quite impressive.
  • FDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.40%.
  • FDA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.51% yearly.
EPS 1Y (TTM)70.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.95%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-9.81%
Revenue growth 5Y-17.51%
Sales Q2Q%38.18%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FDA.MI Yearly Revenue VS EstimatesFDA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FDA.MI Yearly EPS VS EstimatesFDA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 0 50 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • FDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDA.MI Price Earnings VS Forward Price EarningsFDA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 98.20% of the companies in the same industry are more expensive than FDA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.07
EV/EBITDA N/A
FDA.MI Per share dataFDA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for FDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

FIDIA SPA / FDA.MI FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FDA.MI.


What is the valuation status for FDA stock?

ChartMill assigns a valuation rating of 2 / 10 to FIDIA SPA (FDA.MI). This can be considered as Overvalued.


How profitable is FIDIA SPA (FDA.MI) stock?

FIDIA SPA (FDA.MI) has a profitability rating of 2 / 10.